The insulin receptor from human brain tumors of glial origin was examined for the first time using intact cells (from an established cultured human glioblastoma cell line) and partially purified solubilized membranes (from cultured cells and freshly isolated human brain tumors). The structure of the glial insulin receptor subunits was assessed by affinity cross-linking of 125I-insulin with the a-subunit of the receptor, neuraminidase treatment of the cross-linked receptor, behavior of the receptor on lectin columns, and electrophoretic mobility of the phosphorylated ,8-subunit. The functions of the insulin receptor were examined by measuring specific "SI-insulin binding (receptor concentration, affinity, specificity, pH-, time-, and temperature dependence), insulin-induced down-regulation of the receptor, insulin-stimulated autophosphorylation of the 13-subunit, and phosphorylation of exogenous substrates as well as insulin-stimulated glucose uptake in glioblastoma cells. All of these properties were typical for the insulin receptor from target tissues for insulin action. The insulin receptor of the normal human brain showed the altered electrophoretic mobility and lack of neuraminidase sensitivity of its a-subunit previously reported for the rat brain receptor. There was no difference, however, in the functions of the receptor subunits (binding, phosphorylation) from the normal brain tissue and the eight human gliomal tumors. Since the glial elements compose a majority of the brain cells, the "normal" structure and function of their insulin receptor might provide a key to understanding the role of insulin in the carbohydrate metabolism of the human central nervous system.
Introduction
Traditionally, the central nervous system has not been considered a target tissue for insulin action. A major difficulty with most of the previous studies has been the use of preparations from brain containing heterogeneous cell populations. Since the various components of the whole brain homogenates, brain slices, or membranes (neuronal, glial, and vascular) possess different metabolic and functional properties, it is difficult to dissect the role of insulin in the glucose metabolism of any specific central nervous component. A regulatory role of insulin during fetal brain growth and development (1, 2) as well as its role in neurotransmission has been postulated (3) . Despite the presence of the blood-brain barrier, insulin has been identified within the central nervous system (4) . This finding, coupled with the presence of specific insulin receptors in the various components of the rat, rabbit, mouse, and neonatal human brain (1, 2, 5, 6) , suggests a function of this hormone in the mammalian central nervous system.
Extensive studies have compared the properties of "peripheral" (classic target tissues for insulin action) and "central" (brain) insulin receptors. Functional properties ofthe a-subunit of the insulin receptor, such as the binding kinetic parameters, pH optima, time, and temperature dependence, and specificity of insulin binding, are indistinguishable from the peripheral receptors (1, 2, 5, 7) . In contrast, other properties of adult rodent brain receptor, such as its apparent inability to down-regulate after exposure to high insulin concentration (7, 8) , differ from those of peripheral insulin receptors. The structure ofthe receptor's a-subunit in rat brain differs from that of other tissues: the electrophoretic mobility of the a-subunit covalently labeled with '25I-insulin is consistently more rapid (Mr-115,000 vs.
130,000-135,000 for the peripheral receptor) (9) (10) (11) (12) . In addition, neuraminidase treatment, removing sialic acid residues, failed to alter the electrophoretic properties of the a-subunit of the brain receptor while significantly decreasing the apparent molecular weight of the a-subunit of the peripheral receptors (10, 1 1), suggesting a difference of glycosylation of the two types of insulin receptors. The other, 1-subunit of the insulin receptor has also been studied in the rat brain and found to possess the usual functional (insulin-stimulated autophosphorylation and tyrosine kinase activity) properties (9, 13) . Structural studies of the 13-subunit ofthe brain receptor revealed either a slightly lower (10, 13) or identical (9) apparent molecular weight (Mr) when compared with nonneural tissues.
Heterogeneity of tissues studied makes it difficult to identify the precise role of any particular component of the central nervous system in insulin action. In an attempt to address this question, Clarke et al. (14) demonstrated specific insulin receptors and insulin-stimulated 2-deoxy-D-glucose uptake by cultured neonatal glial cells from rat brain. Since insulin did not stimulate this uptake in cultures of neuronal cells, a functional difference between the glial and neuronal insulin receptors was suggested.
Several growth factor and hormone receptors possessing tyrosine-specific protein kinase activity are thought to play a role in cell transformation or differentiation. Indeed, Libermann et al. (15) reported that in 20 samples of human brain tumors, expression of the epidermal growth factor (EGF)' was increased compared with control specimens. In a follow-up study (16) In the present study, we analyzed for the first time the structural and functional characteristics ofthe insulin receptors from cultured human glioblastoma cells as well as from freshly isolated human brain tumors of glial origin. Our results show that all properties of the human nonneuronal insulin receptors mimic those of peripheral tissues. All gliomal tumors also express the "peripheral" insulin receptors; in this small group of patients we could not correlate the receptor activity with the tumor grade. In addition, the unique features ofthe insulin receptor from the normal human brain, predicted from the rodent model, were identified.
Methods

Cells
Cells ofthe cultured human glioblastoma cell line (S., established March 1981, from a 62-yr-old male with left paraoccipital glioblastoma) were obtained from the Surgical Neurology Branch, National Institute of Neurological and Communicative Disorders and Strokes, National Institutes of Health. Samples offreshly isolated human glial cerebral tumors were obtained from the operating room and processed immediately. Tissue was homogenized in a 0.25 M sucrose buffer in presence of protease inhibitors (17) . The 550 g supernatant was centrifuged at 190,000 g for 90 min. The pellet was resuspended in the binding buffer and used as "crude membranes" as described below. Aliquots of the preparations were solubilized by 1% Triton X-100 (New England Nuclear, Boston, MA) and spun at 120,000 g for 45 min. Portions ofthe solubilized membranes were used for some studies, and the remainder was then processed by wheat-germ agglutinin coupled to agarose chromatography (18) . The solubilized, lectin-purified samples were used for both the binding and phosphorylation experiments. Protein content of the preparations was determined by the Bio-Rad method (Bio-Rad Laboratories, Richmond, CA 
Cross-linking of 251-insulin to insulin receptors
Cross-linking was performed using a modification ofthe method ofPilch and Czech (24). Human brain and glioblastoma membranes were prepared as described above. Membranes (final concentration 2.5 mg/ml) and '251-insulin (final concentration 10 ng/ml) were incubated overnight at 4VC. Incubations were terminated by centrifugation at 20,000 g at 4VC. Membrane pellets were resuspended and washed twice in bovine serum albumin-free Krebs-Ringer phosphate buffer (KRP), pH 7.8. Crosslinking was performed in KRP, pH 7.8, in the presence of0.1 mM disuccinimidyl suberate (DSS) (Pierce Chemical Co., Rockford, IL) for 16 min on ice and was terminated by 100mM Tris with 10 mM EDTA, pH 7.4. Pellets were resuspended in 50mM Hepes, pH 7.6, and solubilized by stirring on ice for 3 h with 1% Triton X-100 with 1 mM phenylnethylsulfonyl fluoride (PMSF). Samples were ultracentrifuged at 180,000 g for 30 min at 4°C. Anti-insulin receptor antibody (B-10; 1:100) was used for immunoprecipitation as described previously (17) . The crosslinked receptors were subjected to SDS-PAGE under reducing conditions according to Laemmli (23) . The acrylamide concentration ofthe resolving gel was 7.5%, while that of the stacking gel was 5%.
Neuraminidase digestion ofcross-linked receptors
Receptors from normal human brain, glioblastoma, and human erythrocytes were cross-linked to '25I-insulin as described above. Neuraminidase digestion was performed using a modification of the method of Hendricks et al. (11) . Before solubilization, the pellets were resuspended in I ml 5 mM 2(N-morpholino) ethanesulfonic acid and I mM CaCl2 in the presence or absence of 2.5 units of neuraminidase (type VII) from Clostridium perfringens (Sigma Chemical Co.). Digestion was carried out at 370C for 30 minin the absence ofprotease inhibitors for the brain preparation but in the presence of 2 mM PMSF, 10 jig/ml leupeptin, 0.5 U/ml a2-macroglobulin, 10 jig/ml pepstatin A, and I mM N-ethylmaleimide (Sigma Chemical Co.) for the erythrocyte and glioblastoma preparations. The pellets were washed once in KRP, pH 7.8, and solubilized, immunoprecipitated, and subjected to SDS-PAGE.
Cross-linking of 12SI-insulin to the partially purified insulin receptor Solubilized, wheat-germ agglutinin-purified membranes were prepared as above. About 100 Mg of protein was used in each tube. Samples were preincubated with '25l-insulin in the absence or presence of excess unlabeled insulin (100 Mug/ml) at 4VC for 16 h. To separate the bound from free insulin, samples were run on G-25M Sephadex columns (Pharmacia Fine Chemicals, Uppsala, Sweden) and 1-ml fractions collected. Fractions with the highest radioactivity (usually No. 5) were used for the crosslinking studies in presence of 0.1 mM DSS as described above. After immunoprecipitation with anti-receptor antibody, SDS-PAGE and autoradiography were used to estimate the apparent molecular weight of the cross-linked a-subunit of the insulin receptor.
Degradation of'25I-insulin by the human glioblastoma cells Degradation of'"I-insulin by the cultured glioblastoma cells was assessed as described previously (19) . Briefly, tracer degradation by both the incubation medium and by the cells was measured by TCA precipitability after a 3-h incubation at 1 5°C. Less than 5% of'25I-insulin was degraded by the medium after the 3-h incubation. About 7% of the tracer was degraded by the cells after the 3-h incubation at 15°C.
Insulin-stimulated glucose uptake
The uptake of D-glucose was studied using cultured human glioblastoma cells (cellline S. Insulin binding studies were also done with crude membranes and solubilized, wheat-germ agglutinin-purified membranes from the glioblastoma cells (Fig. 2) . In contrast with the report of Heidenreich et al. (10) , all specific insulin binding activity was recovered in the lectin-column eluate; no significant insulin binding was measured in the flow-through of the wheat germ agglutinin column. Mean insulin concentration required to inhibit 50%S of '25I-insulin binding was 3.7 ng/ml for the solubilized, lectin-purified preparations from the cultured glioblastoma cells.
We next examined insulin binding to the insulin receptor from freshly obtained cerebral gliomas from eight male patients. Clinical parameters of the subjects are shown in Table I . One of the patients (No. 4) underwent a frontal lobectomy during the brain surgery; the histologically normal tissue served as a source of "normal brain." Crude membranes were prepared from the gliomal tissues; no attempt was made to separate microvessels from the glia. Specific '25I-insulin binding studies were carried out with these membranes. No clear correlation could be established between the amount of insulin bound per milligram of the membrane protein and the tumor grade, location, or patient's age. Concentration of insulin required for the 50% inhibition of '25I-insulin binding ranged from 1.2 to 9 ng/ml. Results obtained with the normal brain fell within the range obtained with the tumor tissue.
The malignant and normal brain tissue was further processed. Specific '25I-insulin binding was demonstrated with Triton X-100 (1%) solubilized membranes and partially purified (by wheat germ agglutinin coupled to agarose chromatography) receptor preparations (not shown). As in the case of the cultured glioblastoma cells, all specific insulin binding activity was recovered in the lectin column eluates. When expressed per standard amount ofprotein, the specific I251-insulin binding to the partially purified insulin receptors from the various tumors was remarkably similar and did not differ from the normal brain. ID50 range Regulation ofcerebral glial insulin receptors. Studies in the past showed failure of insulin to down-regulate its receptors in rat neuron-enriched cultured brain tissue (7, 8) . When cells of the cultured human glioblastoma line were preincubated with various concentrations ofinsulin at 370C, and 251I-insulin binding was carried out after extensive washing of the cells, the glial insulin receptors were down-regulated by the ambient insulin concentrations (Fig. 3) . Increasing insulin levels during preincubation inhibited subsequent specific '25i-insulin binding. 50% down-regulation occurred after preincubation with -46 ng/ml insulin. In comparison, the cells ofthe human U-937 line, which is known for the rapid and sensitive regulation of the insulin (results not shown). The a-subunit of the IM-9 insulin receptor, representative of peripheral tissues, showed identical electrophoretic mobility on the same gels.
All of the insulin receptors from the freshly isolated glioma tumors yielded a-subunit with Mr 135,000-140,000 (Fig. 4) . Significantly, when membranes from normal brain tissue and from the glioblastoma derived from the brain of the same individual were studied, there was a marked difference in the mobility of the a-subunit of the insulin receptor. The a-subunit of the glioblastoma receptor moved with an M -~140,000, while that of the normal brain had an Mr -18,000 (Fig. 4) , similar to that previously reported with the whole rat brain as well as several regions from the rat brain (9) (10) (11) (12) . In addition, the electrophoretic mobility of the rat brain insulin receptor subunits was not changed by neuraminidase treatment (10, 11) . Therefore, we next assessed the response of normal human brain as well as human glioblastoma receptor to neuraminidase digestion. As shown in Fig. 5 , neuraminidase (2.5 U/mI) treatment resulted in a small (from an Mr 136,000 to 132,000) but significant de- crease in the Mr of the a-subunit of the glioblastoma receptor.
The insulin receptor of a peripheral cell, the erythrocyte, showed identical response to neuraminidase (Fig. 5, Cand D) . In contrast, the cross-linked insulin receptor of the normal human brain migrated more rapidly and did not respond to neuraminidase (Fig. 5, E and F) . Structure andfunction ofthe ,3-subunit. 13-subunit of the insulin receptors from numerous tissues contains tyrosine kinase activity which can be stimulated by insulin (26, 27) . In our study insulin significantly stimulated autophosphorylation of the cultured glioblastoma 1-subunit (Fig. 6) . The time-, temperature-, and insulin concentration-dependence as well as ionic requirements for the optimal activity of the receptor kinase were identical for the glioblastoma preparation to those previously reported with other tissues (17, 22, 28) . The apparent molecular weight of the 13-subunit of the glioblastoma insulin receptor, at -95,000, was typical of the receptors of peripheral cells. Insulinactivated receptor kinase is capable of phosphorylating exogenous substrates (27) (28) (29) . The partially purified glioblastoma receptor also contained insulin-sensitive kinase activity toward artificial substrates. Insulin at 10-8 M stimulated phosphorylation of casein -2.5-fold by this preparation (Fig. 7) . In addition, insulin (10-8 M) also stimulated phosphorylation of a substrate containing tyrosine as the only phosphorylatable amino acid residue, poly (GluNa80Tyr20), -3.75-fold in the presence of (y-32P) ATP and 20 mM Mg2+ (Fig. 7) . Thus, the human glioblastoma insulin receptor contained functionally and structurally normal 13-subunit.
Analogous results were obtained with the partially purified insulin receptor from the cerebral gliomas and normal human brain. Insulin significantly increased autophosphorylation of the receptor's 1-subunit as identified by immunoprecipitation with anti-receptor antibody, SDS-PAGE, and autoradiography (Fig.  8) . The optimal insulin effect occurred at a concentration of 1 pg/ml for all freshly isolated tissues examined and was approximately equal in magnitude with all receptor preparations. The electrophoretic mobility of the receptor's 13-subunit from all tumor or normal brain tissues was identical (Mr 95,000). Insulinstimulated phosphorylation of exogenous substrates by the partially purified human brain receptor preparations was next assessed. The insulin dose-response was similar to that seen in the autophosphorylation experiments; the optimal stimulation of the receptor kinase activity occurred with 1 ,ug/ml insulin (Fig.  9) . The receptor kinases from the normal brain and the tumors showed the same insulin sensitivity. No insulin-stimulated kinase activity was detected in the lectin column flow-through collection.
The insulin-stimulated tyrosine kinase activities of the partially purified insulin receptors from the normal brain and the patients' gliomas were compared. As we previously discussed (17) , the optimal expression of the insulin-stimulated receptor kinase activity involves the insulin-stimulated increment in the enzyme activity expressed per unit of the receptor binding. plex possessed a more rapid electrophoretic mobility; exposure to neuraminidase failed to alter the electrophoretic properties of the a-subunit of the brain receptors, and whole brain and neuronal insulin receptors did not down-regulate after a chronic exposure to insulin. We tested, with human tissue, the predictions from the rat brain model and extended the studies to the insulin receptors from normal human brain and cerebral gliomas. To avoid the problems inherent in dealing with mixed cell populations, we first studied properties of the insulin receptors from cultured human cells of purely glial origin. The glial elements compose up to 85% of the brain cells (14) . We found that all properties ofthe human glioblastoma insulin receptors were indistinguishable from those of peripheral target tissues. We identified specific insulin receptors with binding parameters (receptor affinity constants, shape of the Scatchard plot, pH-, time-, and temperature-dependence, as well as specificity) typical of peripheral target tissues for insulin. The a-subunit of the glioblastoma insulin receptor (from intact cells, crude membranes, and partially purified receptor) cross-linked with '25I-insulin showed electrophoretic mobility identical to that of peripheral tissues. In addition, the insulin receptor ofthe glioblastoma clearly downregulated after a 3-h exposure to as little as 10 ng/ml insulin. of the glial receptor's a-subunit in the same fashion as that of a peripheral receptor. Significantly, when preparations ofthe malignant and normal portions of the same lobe from the brain of the same patient were examined, we showed major differences between the two types oftissue in the apparent molecular weight ofthe a-subunits and their response to neuraminidase. The "whole brain" preparation behaved as predicted by the rat brain model (10, 1 1): markedly faster electrophoretic mobility and failure to respond to neuraminidase. In contrast, there were no differences seen between the normal human brain and glial tumor tissue in the level of specific insulin binding, receptor affinity, structure of the (3-subunit, or its insulin-stimulated kinase activity. The finding of identical insulin binding activity per unit of protein of the normal and malignant brain tissue despite the marked difference in both the structure of the binding (a) subunit ofthe insulin receptor deserves a comment. It has been assumed that the lower apparent molecular weight ofthe brain receptor's a-subunit is due to its decreased or absent neuraminidase-sensitive sialic acid content (10) (11) (12) . In rat adipocytes removal of sialic acid preserves insulin binding but impairs insulin action (32, 33) . We have reported that in the cultured human monocytelike cell (U-937) and freshly isolated human monocytes the altered apparent molecular weight of the a-subunit did not change insulin binding (34) . Ifthe structural differences are due to altered posttranslational glycosylation of the brain and peripheral receptors, these changes might not take place in the binding domain ofthe a-subunit ofthe insulin receptor. Alternatively, our methods of assaying the specific insulin binding might not be sensitive enough to detect subtle changes in binding.
One puzzling aspect of the structural studies of the a-subunit remains to be solved. Since the glial elements of the brain comprise the majority of the cells in the whole brain, why do we detect only one, the "central," '251-insulin-labeled species on the autoradiographs of the cross-linking studies of the receptor from the normal brain? Is it possible that this reflects an inhibitory influence of the neuronal elements on the glial receptors in the in vivo setting or during the preparation of the samples? It is unlikely, from our results, that a major discrepancy in the affinity of the neuronal and glial receptors for insulin could explain the predominance of the "central" type of the receptor's a-subunit.
To investigate metabolic consequences of the presence of the typical insulin receptors on the human glial cells, we measured the effect of insulin on glucose uptake. As Figure 9 . Insulin-stimulated tyrosine kinase activity of the insulin receptor from normal human brain and cerebral glioblastoma. Partially purified insulin receptor preparations of normal brain tissue and glioblastoma from the same subject (case no. 4) were preincubated without or with insulin at 22°C for 30 min (see Methods). Phosphorylation of poly (GluNar0Tyr0) in the presence of (7-32P)ATP and Mg2e of insulin binding to these receptors can be measured in the glioblastoma cells.
Crude membrane preparations from glial tumors of our patients contained high specific EGF binding activity, as also reported by Libermann et al. (15) . It In summary, the insulin receptors of the cultured human glioblastoma cell line and freshly isolated human brain tumors of glial origin are indistinguishable from the typical peripheral receptors of target tissues for insulin. The insulin receptor ofthe normal human brain differs from the peripheral receptor in the electrophoretic mobility of its a-subunit as well as its failure to respond to neuraminidase treatment, as was predicted by the rodent brain model.
